Targeted systemic delivery of siRNA to cervical cancer model using cyclic RGD-installed unimer polyion complex-assembled gold nanoparticles

Journal of Controlled Release

Volumn 244, Issue , 2016, Pages 247-256

  Yi, Yu ^a   Kim, Hyun Jin ^b   Mi, Peng ^c,d   Zheng, Meng ^a,e   Takemoto, Hiroyasu ^f   Toh, Kazuko ^d   Kim, Beob Soo ^a   Hayashi, Kotaro ^d   Naito, Mitsuru ^b   Matsumoto, Yu ^b   Miyata, Kanjiro ^a,b   Kataoka, Kazunori ^a,d  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c SICHUAN UNIVERSITY   (China)

^d Kawasaki Institute of Industry Promotion   (Japan)

^e HENAN UNIVERSITY   (China)

^f TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

Cancer therapy; cRGD peptide; Gold nanoparticle; siRNA delivery; Unimer polyion complex

Indexed keywords

AMINO ACIDS; DISEASES; ENDOTHELIAL CELLS; GOLD NANOPARTICLES; LANTHANUM COMPOUNDS; METAL NANOPARTICLES; ONCOLOGY; PEPTIDES; POLYETHYLENE GLYCOLS; RNA; TUMORS; VIRUSES;

CANCER THERAPY; NARROW DISTRIBUTION; POLYION COMPLEX; SIRNA DELIVERY; SMALL INTERFERING RNA (SIRNA); SYSTEMIC ADMINISTRATION; SYSTEMIC DELIVERIES; TARGETING EFFICACIES;

IODINE COMPOUNDS;

ARGINYLGLYCYLASPARTIC ACID; GOLD NANOPARTICLE; MACROGOL; SMALL INTERFERING RNA; THIOCTIC ACID; CYCLIC ARGININE-GLYCINE-ASPARTIC ACID PEPTIDE; CYCLOPEPTIDE; DNA BINDING PROTEIN; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18; GOLD; MACROGOL DERIVATIVE; METAL NANOPARTICLE; MONOMETHOXYPOLYETHYLENEGLYCOL-POLYLACTIDE BLOCK COPOLYMER; ONCOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOACCUMULATION; CANCER INHIBITION; CANCER MODEL; CELL SURFACE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; FEMALE; GENE SILENCING; HELA CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; MOUSE MODEL; NONHUMAN; ONCOGENE; PAPILLOMAVIRIDAE; PARTICLE SIZE; PRIORITY JOURNAL; RNA INTERFERENCE; UTERINE CERVIX CANCER; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DRUG EFFECTS; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR VOLUME; UTERINE CERVIX TUMOR;

ANIMALS; DNA-BINDING PROTEINS; FEMALE; GOLD; HELA CELLS; HUMANS; METAL NANOPARTICLES; MICE, INBRED BALB C; MICE, NUDE; ONCOGENE PROTEINS, VIRAL; PEPTIDES, CYCLIC; POLYETHYLENE GLYCOLS; RNA, SMALL INTERFERING; THIOCTIC ACID; TUMOR BURDEN; UTERINE CERVICAL NEOPLASMS;

EID: 84995480381     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2016.08.041     Document Type: Article

References (55)

1. [1] Elbashir, S.M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., Tuschl, T., Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411 (2001), 494–498.
2. [2] Aagaard, L., Rossi, J.J., RNAi therapeutics: principles, prospects and challenges. Adv. Drug Deliv. Rev. 59 (2007), 75–86.
3. [3] Resnier, P., Montier, T., Mathieu, V., Benoit, J.P., Passirani, C., A review of the current status of siRNA nanomedicines in the treatment of cancer. Biomaterials 34 (2013), 6429–6443.
4. [4] Christie, R.J., Miyata, K., Matsumoto, Y., Nomoto, T., Menasco, D., Lai, T.C., et al. Effect of polymer structure on micelles formed between siRNA and cationic block copolymer comprising thiols and amidines. Biomacromolecules 12 (2011), 3174–3185.
5. [5] Falamarzian, A., Xiong, X., Uludag, H., Lavasanifar, A., Polymeric micelles for siRNA delivery. J. Drug Deliv. Sci. Technol. 22 (2012), 43–54.
6. [6] Liu, X., Sun, C., Yang, X., Wang, J., Polymeric-micelle-based nanomedicine for siRNA delivery. Part. Part. Syst. Charact. 30 (2013), 211–228.
7. [7] Jhaveri, A.M., Torchilin, V.P., Multifunctional polymeric micelles for delivery of drugs and siRNA. Front. Pharmacol., 5, 2014, 77.
8. [8] Tseng, Y.C., Mozumdar, S., Huang, L., Lipid-based systemic delivery of siRNA. Adv. Drug Deliv. Rev. 61 (2009), 721–731.
9. [9] Schroeder, A., Levins, C.G., Cortez, C., Langer, R., Anderson, D.G., Lipid-based nanotherapeutics for siRNA delivery. J. Intern. Med. 267 (2010), 9–21.
10. [10] Kanasty, R., Dorkin, J.R., Vegas, A., Anderson, D., Delivery materials for siRNA therapeutics. Nat. Mater. 12 (2013), 967–977.
11. [11] Giljohann, D.A., Seferos, D.S., Prigodich, A.E., Patel, P.C., Mirkin, C.A., Gene regulation with polyvalent siRNA-nanoparticle conjugates. J. Am. Chem. Soc. 131 (2009), 2072–2073.
12. [12] Lytton-Jean, A.K., Langer, R., Anderson, D.G., Five years of siRNA delivery: spotlight on gold nanoparticles. Small 7 (2011), 1932–1937.
13. [13] Cutler, J.I., Auyeung, E., Mirkin, C.A., Spherical nucleic acids. J. Am. Chem. Soc. 134 (2012), 1376–1391.
14. [14] Ku, S.H., Kim, K., Choi, K., Kim, S.H., Kwon, I.C., Tumor-targeting multifunctional nanoparticles for siRNA delivery: recent advances in cancer therapy. Adv. Healthc. Mater. 3 (2014), 1182–1193.
15. [15] Pittella, F., Cabral, H., Maeda, Y., Mi, P., Watanabe, S., Takemoto, H., et al. Systemic siRNA delivery to a spontaneous pancreatic tumor model in transgenic mice by PEGylated calcium phosphate hybrid micelles. J. Control. Release 178 (2014), 18–24.
16. [16] Conde, J., Ambrosone, A., Hernandez, Y., Tian, F., McCully, M., Berry, C.C., et al. 15 years on siRNA delivery: beyond the state-of-the-art on inorganic nanoparticles for RNAi therapeutics. Nano Today 10 (2015), 421–450.
17. [17] Wittrup, A., Lieberman, J., Knocking down disease: a progress report on siRNA therapeutics. Nat. Rev. Genet. 16 (2015), 543–552.
18. [18] Matsumura, Y., Maeda, H., A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46 (1986), 6387–6392.
19. [19] Kataoka, K., Harada, A., Nagasaki, Y., Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv. Drug Deliv. Rev. 47 (2001), 113–131.
20. [20] Matsumura, Y., Kataoka, K., Preclinical and clinical studies of anticancer agent-incorporating polymer micelles. Cancer Sci. 100 (2009), 572–579.
21. [21] Cabral, H., Matsumoto, Y., Mizuno, K., Chen, Q., Murakami, M., Kimura, M., et al. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat. Nanotechnol. 6 (2011), 815–823.
22. [22] Tang, L., Yang, X., Yin, Q., Cai, K., Wang, H., Chaudhury, I., et al. Investigating the optimal size of anticancer nanomedicine. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 15344–15349.
23. [23] Cabral, H., Makino, J., Matsumoto, Y., Mi, P., Wu, H., Nomoto, T., et al. Systemic targeting of lymph node metastasis through the blood vascular system by using size-controlled nanocarriers. ACS Nano 9 (2015), 4957–4967.
24. [24] Anraku, Y., Kishimura, A., Yamasaki, Y., Kataoka, K., Living unimodal growth of polyion complex vesicles via two-dimensional supramolecular polymerization. J. Am. Chem. Soc. 135 (2013), 1423–1429.
25. [25] Kim, H.J., Takemoto, H., Yi, Y., Zheng, M., Maeda, Y., Chaya, H., et al. Precise engineering of siRNA delivery vehicles to tumors using polyion complexes and gold nanoparticles. ACS Nano 8 (2014), 8979–8991.
26. [26] Hayashi, K., Chaya, H., Fukushima, S., Watanabe, S., Takemoto, H., Osada, K., et al. Influence of RNA strand rigidity on polyion complex formation with block catiomers. Macromol. Rapid Commun. 37 (2016), 486–493.
27. [27] Allen, T.M., Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer 2 (2002), 750–763.
28. [28] Farokhzad, O.C., Cheng, J., Teply, B.A., Sherifi, I., Jon, S., Kantoff, P.W., et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 6315–6320.
29. [29] Torchilin, V., Antibody-modified liposomes for cancer chemotherapy. Expert Opin. Drug Deliv. 5 (2008), 1003–1025.
30. [30] Bertrand, N., Wu, J., Xu, X., Kamaly, N., Farokhzad, O.C., Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv. Drug Deliv. Rev. 66 (2014), 2–25.
31. [31] Danhier, F., Le Breton, A., Preat, V., RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis. Mol. Pharm. 9 (2012), 2961–2973.
32. [32] Arap, W., Pasqualini, R., Ruoslahti, E., Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279 (1998), 377–380.
33. [33] Schiffelers, R.M., Ansari, A., Xu, J., Zhou, Q., Tang, Q., Storm, G., et al. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res., 32, 2004, e149.
34. [34] Christie, R.J., Matsumoto, Y., Miyata, K., Nomoto, T., Fukushima, S., Osada, K., et al. Targeted polymeric micelles for siRNA treatment of experimental cancer by intravenous injection. ACS Nano 6 (2012), 5174–5189.
35. [35] Doorbar, J., Quint, W., Banks, L., Bravo, I.G., Stoler, M., Broker, T.R., et al. The biology and life-cycle of human papillomaviruses. Vaccine 30S (2012), F55–F70.
36. [36] Nishida, H., Matsumoto, Y., Kawana, K., Christie, R.J., Naito, M., Kim, B.S., Systemic delivery of siRNA by actively targeted polyion complex micelles for silencing the E6 and E7 human papillomavirus oncogenes. J. Control. Release 231 (2016), 29–37.
37. [37] Oba, M., Fukushima, S., Kanayama, N., Aoyagi, K., Nishiyama, N., Koyama, H., et al. Cyclic RGD peptide-conjugated polyplex micelles as a targetable gene delivery system directed to cells possessing alphavbeta3 and alphavbeta5 integrins. Bioconjug. Chem. 18 (2007), 1415–1423.
38. [38] Zheng, M., Zhong, Y., Meng, F., Peng, R., Zhong, Z., Lipoic acid modified low molecular weight polyethylenimine mediates nontoxic and highly potent in vitro gene transfection. Mol. Pharm. 8 (2011), 2434–2443.
39. [39] Accardi, R., Rubino, R., Scalise, M., Gheit, T., Shahzad, N., Thomas, M., et al. E6 and E7 from human papillomavirus type 16 cooperate to target the PDZ protein Na/H exchange regulatory factor 1. J. Virol. 85 (2011), 8208–8216.
40. [40] Harada, A., Kataoka, K., Formation of polyion complex micelles in an aqueous milieu from a pair of oppositely-charged block copolymers with poly(ethylene glycol) segments. Macromolecules 28 (1995), 5294–5299.
41. [41] Haiss, W., Thanh, N.T., Aveyard, J., Fernig, D.G., Determination of size and concentration of gold nanoparticles from UV–Vis spectra. Anal. Chem. 79 (2007), 4215–4221.
42. [42] Walkey, C.D., Olsen, J.B., Guo, H., Emili, A., Chan, W.C., Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake. J. Am. Chem. Soc. 134 (2012), 2139–2147.
43. [43] Ho, C.M., Chien, T.Y., Huang, S.H., Lee, B.H., Chang, S.F., Integrated human papillomavirus types 52 and 58 are infrequently found in cervical cancer, and high viral loads predict risk of cervical cancer. Gynecol. Oncol. 102 (2006), 54–60.
44. [44] Livak, K.J., Schmittgen, T.D., Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25 (2001), 402–408.
45. [45] Miura, Y., Takenaka, T., Toh, K., Wu, S., Nishihara, H., Kano, M.R., et al. Cyclic RGD-linked polymeric micelles for targeted delivery of platinum anticancer drugs to glioblastoma through the blood-brain tumor barrier. ACS Nano 7 (2013), 8583–8592.
46. [46] Yang, Q., Jones, S.W., Parker, C.L., Zamboni, W.C., Bear, J.E., Lai, S.K., Evading immune cell uptake and clearance requires PEG grafting at densities substantially exceeding the minimum for brush conformation. Mol. Pharm. 11 (2014), 1250–1258.
47. [47] Suk, J.S., Xu, Q., Kim, N., Hanes, J., Ensign, L.M., PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv. Drug Deliv. Rev. 99 (2016), 28–51.
48. [48] Uchida, K., Otsuka, H., Kaneko, M., Kataoka, K., Nagasaki, Y., A reactive poly(ethylene glycol) layer to achieve specific surface plasmon resonance sensing with a high S/N rtio: the substantial role of a short underbrushed PEG layer in minimizing nonspecific adsorption. Anal. Chem. 77 (2005), 1075–1080.
49. [49] Simpson, C.A., Agrawal, A.C., Balinski, A., Harkness, K.M., Cliffel, D.E., Short-chain PEG mixed monolayer protected gold clusters increase clearance and red blood cell counts. ACS Nano 5 (2011), 3577–3584.
50. [50] Ishii, T., Miyata, K., Anraku, Y., Naito, M., Yi, Y., Jinbo, T., et al. Enhanced target recognition of nanoparticles by cocktail PEGylation with chains of varying lengths. Chem. Commun. 52 (2016), 1517–1519.
51. [51] Cheng, R., Feng, F., Meng, F., Deng, C., Feijen, J., Zhong, Z., Glutathione-responsive nano-vehicles as a promising platform for targeted intracellular drug and gene delivery. J. Control. Release 152 (2011), 2–12.
52. [52] Shayakhmetov, D.M., Eberly, A.M., Li, Z., Lieber, A., Deletion of penton RGD motifs affects the efficiency of both the internalization and the endosome escape of viral particles containing adenovirus serotype 5 or 35 fiber knobs. J. Virol. 79 (2005), 1053–1061.
53. [53] Hall, A.H.S., Alexander, K.A., RNA interference of human papillomavirus type 18 E6 and E7 induces senescence in HeLa cells. J. Virol. 77 (2003), 6066–6069.
54. [54] Newman, P.J., The biology of PECAM-1. J. Clin. Invest. 99 (1997), 3–8.
55. [55] Kawamura, W., Miura, Y., Kokuryo, D., Toh, K., Yamada, N., Nomoto, T., et al. Density-tunable conjugation of cyclic RGD ligands with polyion complex vesicles for the neovascular imaging of orthotopic glioblastomas. Sci. Technol. Adv. Mater., 16, 2015, 035004.